Jan 1 2021
BioTheryX, Inc. renews its confidence with INOVOTION for preclinical in vivo efficacy evaluation of their compounds.
For BioTheryX, Inc., a clinical-stage biopharmaceutical company focused on restoring protein homeostasis
through protein modulation, 2020 has been a fruitful year!
The company launched a Phase 1 Clinical Trial of BTX-A51 in January and announced a $35 Million
Series D financing in July.
We are proud to contribute to BioTheryX, Inc. preclinical efforts!
If you also wish to collaborate with us, please, feel free to Contact us
Nov 13
2024
Come see us at the EPAA
Come see us at the EPAA (European Partnership for Alternative Approaches to Animal Testing) 2024 Annual Conference INOVOTION will be at the European Partnership for Alternative Approaches to Animal Testing (EPAA) Annual Conference 2024, November […]
Nov 6-10
2024
Come see us at the SITC
Come see us at the SITC (Society for Immunotherapy of Cancer) 39th Annual Meeting, November 6-10, 2024, in Houston! SITC 2024 is the world’s leading showcase of advances in cancer immunology and immunotherapy, bringing together […]
Nov 4-6
2024
Come see us at Bio-Europe Fall
